Myofilament calcium regulation in human myocardium

Circulation

Volumn 101, Issue 14, 2000, Pages 1679-1685

  Hajjar, Roger J ^a   Schwinger, Robert H G ^c   Schmidt, Ulrich ^a   Kim, Catherine S ^a,b   Lebeche, Djamel ^b   Doye, Angelia A ^a,b   Gwathmey, Judith K ^a,b,c  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Gwathmey Inc   (United States)

^c Building E ^*

Author keywords

Calcium; cGMP; Heart failure; Myocardium; Myocytes

Indexed keywords

CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC GMP;

ARTICLE; CALCIUM CELL LEVEL; ENZYME ACTIVITY; HEART FAILURE; HEART MUSCLE CONTRACTILE FORCE; HUMAN; HUMAN TISSUE; MYOFILAMENT; PATHOGENESIS; PH; PRIORITY JOURNAL;

EID: 0034636114     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.101.14.1679     Document Type: Article

References (41)

1. Gwathmey JK, Copelas L, MacKinnon R, Schoen FJ, Feldman MD, Grossman W, Morgan JP. Abnormal intracellular calcium handling in myocardium from patients with end-stage heart failure. Circ Res. 1987; 61:70-76.
2. Schmidt U, Hajjar RJ, Helm PA, Kim CS, Doye AA, Gwathmey JK. Contribution of abnormal sarcoplasmic reticulum ATPase activity to systolic and diastolic dysfunction in human heart failure. J Mol Cell Cardiol. 1998;30:1929-1937.
3. Gwathmey JK, Slawsky MT, Hajjar RJ, Briggs GM, Morgan JP. Role of intracellular calcium handling in force-interval relationships of human ventricular myocardium. J Clin Invest. 1990;85:1599-1613.
4. Mulieri LA, Hasenfuss G, Leavitt B, Allen PD, Aplert NR. Altered myocardial force-frequency relation in human heart failure. Circulation. 1992;86:2017-2018.
5. Pieske B, Kretschmann B, Meyer M, Holubarsch C, Weirich J, Posival H, Minami K, Just H, Hasenfuss G. Alterations in intracellular calcium handling associated with the inverse force-frequency relation in human dilated cardiomyopathy. Circulation. 1995;92:1169-1178.
6. Solaro RJ, Gao L, Olson CC, Gwathmey JK. Control of myofilament activation in heart failure. Circulation. 1993;87(suppl 7):VII-38-VII-43.
7. Gwathmey JK, Ingwall JS. Basic pathophysiology of congestive heart failure. Cardiol Rev. 1995;3:282-291.
8. 2+ in intact and skinned trabeculae from control and myopathic human hearts. J Clin Invest. 1988;82:1578-1584.
9. 2+ release activity of the sarcoplasmic reticulum in dilated cardiomyopathy. Circulation. 1992;85:518-525.
10. Schwinger RHG, Bohm M, Koch A, Schmidt U, Morano I, Eissner HJ, Uberfuhr P, Reichart B, Erdmann E. The failing human heart is unable to use the Frank-Starling mechanism. Circ Res. 1994;74:959-969.
11. Anderson PAW, Greig A, Mark TM, Malouf NN, Oakeley AE, Ungerleider RM, Allen PD, Kay BK. Molecular basis of human cardiac troponin T isoforms expressed in the developing, adult, and failing heart. Circ Res. 1995;76:681-686.
12. Margossian SS, White HD, Caulfield JB, Norton P, Taylor S, Slayter HS. Light chain 2 profile and activity of human ventricular myosin during dilated cardiomyopathy: identification of a causal agent for impaired myocardial function. Circulation. 1992;85:1720-1733.
13. Anderson PAW, Malouf NN, Oakeley AE, Pagani ED, Allen PD. Troponin T isoform expression in humans. Circ Res. 1991;69: 1226-1233.
14. Alpert NR, Gordon MS. Myofibrillar adenosine triphosphatase activity in congestive heart failure. Am J Physiol. 1962;202:940-946.
15. Pagani ED, Alousi AA, Grant AM, Older TM, Dziuban SW, Allen PD. Changes in myofibrillar content and Mg-ATPase activity in ventricular tissue from patients with heart failure caused by coronary artery disease, cardiomyopathy, or mitral valve insufficiency. Circ Res. 1988;63: 380-385.
16. Hajjar RJ, Gwathmey JK. Cross-bridge dynamics in human ventricular myocardium: regulatory properties of contractivity in the failing heart. Circulation. 1992;86:1819-1826.
17. 2+ sensitivity in intact and skinned muscles from normal and diseased human myocardium. Circ Res. 1990;67:744-752.
18. Solaro RJ, el-Saleh SC, Kentish J, Meyer A, Martin A. Transitions in isoform populations of thick and thin filament proteins and calcium activation of force and ATP hydrolysis by cardiac myofilaments. Prog Clin Biol Res. 1989;315:487-502.
19. Fabiato A. Computer programs for calculating total from specified free or free from specified total ionic concentrations in aqueous solutions containing multiple metals and ligands. Methods Enzymol. 1988;157: 378-391.
20. George WJ, Busuttil RW, Paddock RJ, White LA, Ignarro LJ. Opposing regulatory influences of cyclic guanosine monophosphate and cyclic adenosine monophosphate in the control of cardiac muscle contraction., In: Roy P.-E., Harris P., eds. Recent Advances in Studies on Cardiac Structure and Metabolism. Baltimore, Md: University Park Press; 1975: 243-250.
21. Solaro RJ. Myosin and why hearts fail. Circulation. 1992;85:1945-1947.
22. Solaro RJ. Troponin I, stunning, hypertrophy, and failure of the heart. Circ Res. 1999;84:122-124.
23. Boheler KR, Carrier L, de la Bastie D, Allen PD, Komajda M, Mecardier JJ, Schwartz K. Skeletal actin mRNA increases in the human heart during ontogenic development and is the major isoform of control and failing adult hearts. J Clin Invest. 1991;88:323-330.
24. Nassar R, Malouf NN, Kelly MB, Oakeley AE, Anderson PAW. Force-pCa relation and troponin T isoforms of rabbit myocardium. Circ Res. 1991;69:1470-1475.
25. Morano I, Ritter O, Bonz A, Timek T, Vahl CF, Michel G. Myosin light chain-actin interaction regulates cardiac contractility. Circ Res. 1995;76: 720-725.
26. Veksler V, Ventura-Clapier R. In situ study of myofibrils, mitochondria and bound creatine kinases in experimental cardiomyopathies. Mol Cell Biochem. 1994;133-134:287-298.
27. Veksler VI, Ventura-Clapier R, Lechene P, Vassort G. Functional state of myofibrils, mitochondria, and bound creatine kinase in skinned ventricular fibers of cardiomyopathic hamsters. J Mol Cell Cardiol. 1988;20: 329-342.
28. Liao R, Gwathmey JK, Wang CK. Functional significance of two missense mutations in troponin C found in human myocardium with idiopathic dilated cardiomyopathy. Circulation. 1998;98:1-625. Abstract.
29. Solaro RJ, Holroyde MJ, Herzig JW, Peterson J. Cardiac relaxation and myofibrillar interactions with phosphate and vanadate. Eur Heart J. 1980;1(suppl A):21-27.
30. Herzig J, Peterson JW, Ruegg JC, Solaro RJ. Vanadate and phosphate ions reduce tension and increase cross-bridge kinetics in chemically skinned heart muscle. Biochim Biophys Acta. 1981;672:191-196.
31. Kentish JC. The effects of inorganic phosphate and creatine phosphate on force production in skinned muscles from rat ventricle. J Physiol (Lond). 1986;370:584-604.
32. Gwathmey JK, Hajjar RJ, Solaro RJ. Contractile deactivation and uncoupling of cross-bridges: effects of 2,3-butanedione monoxime on mammalian myocardium. Circ Res. 1991;69:1280-1292.
33. 2+ sensitivity. J Gen Physiol. 1982;79:997-1016.
34. Morano I, Bletz C, Wojciechowski, Ruegg JG. Modulation of cross-bridge kinetics by myosin isoenzymes in skinned human heart fibers. Circ Res. 1991;68:614-618.
35. (2+)-sensitivity of SERCA 2a in failing human myocardium due to reduced serine-16 phospholamban phosphorylation. J Mol Cell Cardiol. 1999;31:479-491.
36. Hunkeler NM, Kullman J, Murphy AM. Troponin I isoform expression in human heart. Circ Res. 1991;69:1409-1414.
37. Sasse S, Brand NJ, Kyprianou P, Dhoot GK, Wade R, Arai M, Periasamy M, Yacoub MH, Barton PJR. Troponin I gene expression during human cardiac development and end-stage heart failure. Circ Res. 1993;72: 932-938.
38. Bohm M, Reiger B, Schwinger RH, Erdmann E. cAMP concentrations, cAMP dependent protein kinase activity, and phospholamban in non-failing and failing myocardium. Cardiovasc Res. 1994;28:1713-1719.
39. Feldman MD, Copelas L, Gwathmey JK, Phillips PJ, Schoen F, Grossman W, Morgan JP. Deficient production of cyclic AMP: pharmacologic evidence of an important cause of contractile dysfunction in patients with end-stage heart failure. Circulation. 1987;75:331-339.
40. 2+-dependent protein kinase. Biochemistry. 1983;209:189-195.
41. Bohm M, Diet F, Kemkes B, Wankerl M, Erdmann E. Inotropic response to DPI 201-106 in the failing human heart. Br J Pharmacol. 1989;98: 275-283.